A Phase 1/2a Clinical Study of KL002 in Treatment of Parkinson's Disease - NCT07929480

Sponsor: Kanglin Biotechnology (Hangzhou) Co., Ltd. Conditions: Parkinson's Disease (PD), PD To assess the safety and tolerability of single doses of KL002 over 78 weeks in subjects with Parkinson's disease。 This is an open-label, non-randomized, phase 1/2a single ascending dose study, consisting of Dose Escalation and Dose Expansion parts, to evaluate the safety, tolerability, and efficacy of KL002 in patients with Parkinson's disease. Eligible subjects will enter the dose escalation part of the study, receive a single stereotactic intraputaminal administration of KL002, and be followed for 18 months in the core study and up to 5 years total in long-term follow-up (LTFU) with safety and efficacy assessments.